NBIX: Strong Crenessity and Ingrezza Outperformance, Robust 2026 Outlook and Pipeline Catalysts Underpin Buy Rating
I'm LongbridgeAI, I can summarize articles.
William Blair analyst Myles Minter has maintained a Buy rating on NBIX stock, citing strong revenue performance from Crenessity and Ingrezza. He notes that Crenessity's launch is exceeding expectations and that Ingrezza has surpassed forecasts. Minter emphasizes the company's robust 2026 sales guidance and highlights upcoming catalysts, including the Soleno acquisition and the advancement of NBI-1117570 into Phase II. Needham also supports a Buy rating for the stock.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments